Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, Chan S, Perren T, Aapro M, Sotiriou C, Piccart MJ, Larsimont D, Isola J; TAX 303 translational study team. Di Leo A, et al. Among authors: larsimont d. Ann Oncol. 2007 Jun;18(6):997-1003. doi: 10.1093/annonc/mdm075. Epub 2007 Mar 17. Ann Oncol. 2007. PMID: 17369602 Free article. Clinical Trial.
Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome.
Lespagnard L, Gancberg D, Rouas G, Leclercq G, de Saint-Aubain Somerhausen N, Di Leo A, Piccart M, Verhest A, Larsimont D. Lespagnard L, et al. Among authors: larsimont d. Int J Cancer. 1999 Jun 21;84(3):309-14. doi: 10.1002/(sici)1097-0215(19990621)84:3<309::aid-ijc19>3.0.co;2-3. Int J Cancer. 1999. PMID: 10371352
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH, Closon-Dejardin MT, Dolci S, Rouas G, Paesmans M, Lobelle JP, Isola J, Piccart MJ. Di Leo A, et al. Among authors: larsimont d. Ann Oncol. 2001 Aug;12(8):1081-9. doi: 10.1023/a:1011669223035. Ann Oncol. 2001. PMID: 11583189 Free article. Clinical Trial.
The predictive value of HER2 in breast cancer.
Piccart M, Lohrisch C, Di Leo A, Larsimont D. Piccart M, et al. Among authors: larsimont d. Oncology. 2001;61 Suppl 2:73-82. doi: 10.1159/000055405. Oncology. 2001. PMID: 11694791 Review.
A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
Hamilton A, Larsimont D, Paridaens R, Drijkoningen M, van de Vijver M, Bruning P, Hanby A, Houston S, Treilleux I, Guastalla JP, Van Vreckem A, Sylvester R, Piccart M. Hamilton A, et al. Among authors: larsimont d. Clin Breast Cancer. 2000 Oct;1(3):233-40; discussion 241-2. doi: 10.3816/CBC.2000.n.020. Clin Breast Cancer. 2000. PMID: 11899648 Clinical Trial.
312 results